NSD1 inactivation defines an immune cold, DNA hypomethylated subtype in squamous cell carcinoma
K. Brennan, J. H. Shin, J. K. Tay, M. Prunello, A. Gentles, J. B. Sunwoo, O. Gevaert
Abstract
Chromatin modifying enzymes are frequently mutated in cancer, resulting in a cascade of epigenetic deregulation. Recent reports indicate that inactivating mutations in the histone methyltransferase NSD1 define an intrinsic subtype of head and neck squamous cell carcinoma (HNSC) that features widespread DNA hypomethylation. Here, we describe a similar DNA hypomethylated subtype of lung squamous cell carcinoma (LUSC) that is enriched for both inactivating mutations and deletions in NSD1. The NSD1 subtype of HNSC and LUSC are highly correlated at the DNA methylation and gene expression levels, with concordant DNA hypomethylation and overexpression of a strongly overlapping set of genes, a subset of which are also hypomethylated in Sotos syndrome, a congenital growth disorder caused by germline NSD1 mutations. Further, the NSD1 subtype of HNSC displays an immune cold phenotype characterized by low infiltration of tumor-associated leukocytes, particularly macrophages and CD8+ T cells, as well as low expression of genes encoding the immunotherapy target PD-1 immune checkpoint receptor and its ligands PD-L1 and PD-L2. Using an in vivo model, we demonstrate that NSD1 inactivation results in a reduction in the degree of T cell infiltration into the tumor microenvironment, implicating NSD1 as a tumor cell-intrinsic driver of an immune cold phenotype. These data have important implications for immunotherapy and reveal a general role of NSD1 in maintaining epigenetic repression.
02 /Specification & Classification
Click any tag to browse matching papersReproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Epigenome dysregulation resulting from NSD1 mutation in head and neck squamous cell carcinoma
Nargess Farhangdoost, Cynthia Horth, … Jacek Majewski·Cell ReportsPeer-reviewed·Feb 1, 2021
- LSD1 inhibition corrects dysregulated MHC-I and dendritic cells activation through IFNγ-CXCL9-CXCR3 axis to promote antitumor immunity in HNSCC
Amit Kumar Chakraborty, Lina Kroehling, … Manish V. Bais·bioRxiv·Mar 17, 2025
- Targeting NAT10 Activates Tumor-Intrinsic Immunity and Suppresses Tumor Progression in Head and Neck Squamous Cell Carcinoma
Thurbu Tshering Lepcha, Nithya Paruchuri, … Netty G. Santoso·bioRxiv·Aug 8, 2026
- NSD1 supports cell growth and regulates autophagy in HPV-negative head and neck squamous cell carcinoma.
Iuliia Topchu, Igor Bychkov, … Yanis Boumber·Cell Death DiscoveryPeer-reviewed·Feb 12, 2024
- Methylation of histone H3 lysine 36 is a barrier for therapeutic interventions of head and neck squamous cell carcinoma.
Lucas D. Caeiro, Yuichiro Nakata, … Lluís Morey·bioRxiv·Nov 6, 2023
- A Novel Syngeneic Mouse Model to Study Immune Evasion in Head and Neck Squamous Cell Carcinoma
Mari Iida, Bridget E. Crossman, … Deric L. Wheeler·bioRxiv·Jul 23, 2026